Background
Cyclin D1 is a critical regulator of the cell cycle and transcriptional processes. Overexpression or overactivity of cyclin D1 is common in human cancers. Cyclin D1 is also expressed in lymphoid tumors such as mantle cell lymphoma (MCL) and multiple myeloma (MM). The expression of cyclin D1 in B-cells in which the protein is physiologically absent, is supposed to be causal in the transformation process. In MCL,
CCND1 (encoding cyclin D1) is activated by the t(11;14)(q13;q32) in almost 100% of cases [
1]. In multiple myeloma (MM), cyclin D1 is expressed in 45–50% of samples but the t(11;14)(q13;q32) is only present in 15% of them [
2]. The human
CCND1 gene encodes two mRNAs species resulting from an alternative splicing: form a [
3] and form b generated by the absence of splicing at the exon 4/intron 4 boundary [
4]. Cyclin D1 protein isoforms differ in the last 55 amino acids of the carboxy-terminus. Cyclin D1a and D1b proteins possess the cyclin box necessary for cyclin-dependent kinase (CDK) binding and enzymatic activity. But the PEST destruction box as well as Thr286, the phosphorylation site of glycogen synthase kinase-3β which promotes the nuclear export of cyclin D1 and its turn-over, are missing in form b [
5,
6]. Recently, it has been shown that cyclin D1 isoforms could display functional differences and importantly that only cyclin D1b facilitates transformation in fibroblasts [
7‐
9]. Considering this putative role in tumorigenesis, we have studied cyclin D1b expression in MCL and MM samples. A common A/G polymorphism described as a modulator of cancer risk is thought to regulate the production of cyclin D1b [
4]. We have also analyzed this relationship in MCL samples.
Discussion
Using standard RT-PCR, we found previously that cyclin D1a and b were coexpressed in MCL patients and in MM cell lines irrespectively of the presence of the t(11;14) translocation [
11]. We now extended this work and analyzed cyclin D1 isoform expression with a real-time quantitative RT-PCR in MM and MCL primary cells and cell lines.
Although cyclin D1 mRNA isoforms are always co-expressed in MCL and in cyclin D1-expressing MM cells, cyclin D1b protein was rarely and faintly expressed in MM samples. By contrast, in MCL cells, cyclin D1b was often present. Thus, post-transcriptional mechanisms regulate cyclin D1b status depending on the B-cell hemopathy.
Cyclin D1a and D1b proteins exhibit the same stability. In previous studies [
7,
8], in transfected models, the calculated half-lives of cyclin D isoforms were also similar and similar to ours. Thus, endogenous and exogenous cyclin D1 isoforms are subjected to the same post-translational regulation. Either the PEST sequence is not strictly necessary for proteolysis through the proteasome machinery which is peculiarly active in MCL [
13] or cyclin D1 can be degraded through another motif. In the case of cell response to stress, cyclin D1 can be degraded through its binding to the anaphase-promoting complex and a RXXL sequence located in the NH2-terminal part of the protein [
14]. This sequence is present in both cyclin D1 isoforms. Such a mechanism could be activated constitutively in MCL cells.
B-cell lymphomas can be induced in transgenic mice expressing a cyclin D1 mutant (T286A) under the control of Eμ enhancer [
15]. This mutant displays a 5-fold longer half-life than cyclin D1 [
16] and is exclusively nuclear. This sub-cellular localization seems to be a prerequisite to transformation. In MCL cells, cyclin D1b localizes both the nuclear and cytoplasmic compartments. In good agreement, endogenous cyclin D1b appears cytoplasmic and nuclear in oesophageal carcinomas [
7] In contrast, in transfected fibroblastic cells, cyclin D1b remains mostly nuclear [
7‐
9]. The simplest explanation is that the nuclear export is subverted by an overexpression of exogenous cyclin D1b.
Cyclin D1b is rarely and faintly expressed in MM and not always detected in MCL ([
17] and our results). Thus, the expression of cyclin D1b is not necessary at least for the maintenance of a tumoral phenotype. Interestingly, the presence of a short cyclin D1 transcript (1.7 kb) lacking the 3'-UTR region responsible for mRNA stability, has been associated with MCL aggressiveness and a poor prognosis [
1]. The relationship between the alternative spliced forms and the short mRNA has to be studied.
In MCL,
CCND1 alternative splicing does not modulate the level of transcripts b. This is consistent with results showing that
CCND1 alternative splicing depends on sample origin [
17]. Moreover, cyclin D1b is transcribed independently of A/G genotype. This indicates that both alleles can splice to form both transcripts. Besides A/G polymorphism,
trans-elements regulate alternative splicing. In good agreement with us, Howe and Lynas also showed that
CCND1 polymorphism does not affect the prognosis of MCL patients [
18].
In breast, sarcoma and colon cancers, with cyclin D1 overexpression and no chromosome 11 alterations, elevated mRNA levels result from a
trans-acting influence of both alleles [
19]. A biallelic expression is seen in MM tumors without the t(11;14) [
2]. In agreement with that observed in MM tumors with t(11;14), only one allele is transcribed in MCL cells, the transcribed allele is likely the structurally altered one.
Acknowledgements
The authors thank Anne Barbaras for expert technical assistance, Prof. Markus Müschen (Heinrich Heine Universität, Düsseldorf, Germany) for the gift of MCL cell lines, Dr Alan J. Diehl (University of Pennsylvania, Philadelphia, USA) for the gift of the R3 antibody. This work was supported by the Ligue Nationale contre le Cancer – Comité du Calvados, Cent pour sang la vie and the Association pour la Recherche contre le Cancer (grants n° 3426 and n° 7791 to BS). JG was the recipient of a scholarship from the Ministère de l'Enseignement Supérieur et de la Recherche.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
SK performed most experiments and JG the others. SK, JG, MR contributed to analysis and interpretation of data and to approval of the manuscript. XT provided patient samples, critically revised the manuscript and approved the manuscript. BS designed experiments, participated to analysis, interpretation of data, wrote the two versions of the paper. All authors read and approved the version 2 of the manuscript.